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Significant Improvement in Quality of Life, Positive Effect
on Sexuality, Lasting Reconstructive Result and Low Rate
of Complications Following Cystocele Correction Using
a Lightweight, Large-Pore, Titanised Polypropylene Mesh
Final Results of a National, Multicentre Observational Study
Signifikante Verbesserung der Lebensqualität, positive Auswirkung
auf die Sexualität, nachhaltiges rekonstruktives Ergebnis und
geringe Komplikationsrate nach Zystozelenkorrektur mittels eines
leichtgewichtigen, großporigen, titanisierten Polypropylennetzes
Finale Ergebnisse einer nationalen, multizentrischen Beobachtungsstudie
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ABSTRACT
Introduction Patients who suffer from pelvic organ prolapse
can experience severe limitations in their quality of life. To im-
prove the quality of life of women affected and achieve a sta-
ble reconstruction, surgical therapy is often indispensable. In
conventional prolapse surgery, the rate of recurrence is high.
For this reason, alloplastic mesh has been implanted increas-
ingly in recent years to reconstruct the anatomy of the pelvic
floor organs. Even if the anatomical result can be significantly
improved as a result, the mesh-induced complications have
been the subject of controversial discussion. In this national,
multicentre study, the quality of life, anatomical result as well
as the rate of complications following the implantation of an
alloplastic mesh for the correction of a cystocele were investi-
gated.
Method Fifty-four patients with symptomatic ≥ grade II were
included in this prospective, national, multicentre study. The
study participants were implanted with a titanised
polypropylene mesh (TiLOOP® PRO A, pfm medical ag). The
follow-up observation period was 12 months. Primary as well
as repeat procedures were taken into account. The anatomic
result of the pelvic floor reconstruction was quantified using
the POP‑Q system. Data on quality of life and sexuality were
collected using validated questionnaires. All complications
which occurred were documented and evaluated by an inde-
pendent committee.
Results On average, the patients were in line with the census.
An improvement in quality of life was able to be determined
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during the study in all domains investigated (p < 0.001, Wil-
coxon test). Minus incorrect entries and incorrect reports, a
total of 19 reports of adverse events in 15 patients were eval-
uated by the end of the study. The rate of recurrence in the
anterior compartment was 4.3%.
Conclusion In the reconstruction of the anatomical position
of the pelvic floor organs given the presence of a symptomat-
ic cystocele, the implantation of a third-generation alloplastic
mesh achieves very good results. Affected patients benefit
from the anatomical stability as well as a significant improve-
ment in quality of life, whereby the risks are justifiable.
ZUSAMMENFASSUNG
Einleitung Patientinnen, die unter einem Descensus genitalis
leiden, können in ihrer Lebensqualität stark eingeschränkt
sein. Um die Lebensqualität betroffener Frauen zu verbessern
und eine stabile Rekonstruktion zu erreichen, ist häufig eine
operative Therapie unumgänglich. Bei der konventionellen
Deszensuschirurgie ist die Rezidivrate hoch. Daher wurden in
den vergangenen Jahren zunehmend alloplastische Netze zur
Rekonstruktion der Anatomie der Beckenbodenorgane im-
plantiert. Auch wenn das anatomische Resultat dadurch deut-
lich verbessert werden konnte, führten die netzinduzierten
Komplikationen zu einer kontroversen Diskussion. In dieser
nationalen, multizentrischen Studie wurden die Lebensquali-
tät, das anatomische Resultat sowie die Komplikationsrate
nach Implantation eines alloplastischen Netzes zur Korrektur
einer Zystozele untersucht.
Methode Vierundfünfzig Patientinnen mit symptomatischer
Zystozele ≥ II° wurden in diese prospektive, nationale, multi-
zentrische Studie eingeschlossen. Den Studienteilnehmerin-
nen wurde ein titanisiertes Polypropylennetz (TiLOOP® PRO
A, pfm medical ag) implantiert. Die Nachbeobachtungszeit
betrug 12 Monate. Sowohl Primär- als auch Rezidiveingriffe
wurden berücksichtigt. Das anatomische Ergebnis der
Beckenbodenrekonstruktion wurde mittels POP‑Q-System
quantifiziert. Daten zur Lebensqualität und Sexualität wurden
mittels validierten Fragebögen erfasst. Alle aufgetretenen
Komplikationen wurden dokumentiert und von einem unab-
hängigen Komitee bewertet.
Ergebnisse Im Durchschnitt entsprachen die Patientinnen
dem Zensus. Eine Verbesserung der Lebensqualität konnte
während der Studie in allen untersuchten Domänen fest-
gestellt werden (p < 0,001, Wilcoxon-Test). Abzüglich Fehlein-
gaben und inkorrekter Berichte wurden bis zum Studienende
insgesamt 19 Meldungen zu unerwünschten Ereignissen bei
15 Patientinnen bewertet. Die Rezidivrate im anterioren Kom-
partiment betrug 4,3%.
Schlussfolgerung Bei der Rekonstruktion der anatomischen
Lage der Beckenbodenorgane bei Vorhandensein einer symp-
tomatischen Zystozele erzielt die Implantation eines alloplas-
tischen Netzes der dritten Generation sehr gute Ergebnisse.
Betroffene Patientinnen profitieren von der anatomischen
Stabilität sowie einer signifikanten Verbesserung der Lebens-
qualität, wobei die Risiken vertretbar sind.
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Pelvic organ prolapse is one of the most common diseases in
women. The risk of suffering prolapse increases with age, BMI,
parity, physical stress over many years, and the stability of the
connective tissue. In many age groups, nearly one out of four
women is affected [1,2]. Not all women affected develop symp-
toms or perceive the symptoms to be detrimental. Others experi-
ence significant impairment of their quality of life due to a change
in bladder and bowel function (symptoms of urgency, inconti-
nence, voiding disorder), the feeling of a foreign body and/or dys-
pareunia, among others [3,4]. The lifetime risk for women to have
to undergo surgical treatment due to pelvic organ prolapse is up
to 20% [5]. Because of demographic changes in society, there will
be an increase in the future in elderly women with symptomatic
prolapse [6]. Therefore, for current and future patients, there
should be a surgical therapy option with low rates of recurrence
and complications, after conservative measures have been ex-
hausted. The surgical reconstruction of the anterior compartment
through tightening of autologous tissue, conventional anterior
colporrhaphy, shows rates of recurrence of up to 50% [3,7,8].
The implantation of alloplastic material significantly improves the
anatomic result and significantly decreases the rate of recurrence
[3,9–11]. However, the mesh implantations were initially associ-
ated with a high rate of complications and adverse events, such as
erosions, painful shrinkage of the implant, dyspareunia and also960 Cadenlate infections [3,9, 12]. Based on these experiences [12], the use
of alloplastic implants in the treatment of prolapse has been the
subject of controversial discussion. According to warnings [12]
from the U.S. authority for food and drug safety (US Department
of Health and Human Services, Food and Drug Administration
[FDA]) in 2011, many manufacturers took their product off the
market, in some cases only in the United States and in some cases
worldwide. In the meantime, alloplastic implants have been pro-
hibited by the FDA for the treatment of prolapse of the anterior
compartment [13]. However, the numbers of mesh-aided sur-
geries have remained constant in Germany [14]. As a result of
the further development of the implants (enlargement of the
pores, reduction of the overall weight), increased experience on
the part of the surgeons, and the improvement in the preparation
and fixation techniques, it has been possible to reduce the num-
ber of complications [3,15]. Studies on these new implants have
already shown a significantly reduced rate of complications and a
significant improvement in quality of life, even beyond a postop-
erative period of up to 36 months for the newer implants [11,16,
17]. The primary endpoint of the study presented here was the
change in quality of life 12 months postoperatively versus preop-
eratively in the case of symptomatic cystocele ≥ grade II following
surgical correction by means of vaginal implantation of a titanised
polypropylene mesh. The previous study with the titanised
polypropylene mesh TiLOOP® Total 6 has already shown a signifi-
cant improvement in quality of life following implantation of thebach-Blome T et al. Significant Improvement in… Geburtsh Frauenheilk 2019; 79: 959–968
mesh for the surgical correction of a cystocele [11,17]. The rates
of recurrence and complications were low [11]. However, an ero-
sion rate of 10.5% was seen [11]. The refined and optimised titan-
ised polypropylene mesh TiLOOP® PRO A is to now be investigated
within the scope of a multicentre observational study with regard
to quality of life as well as the rate of complications and erosion.
Due to the further improvement in material characteristics, it was
assumed that the rate of complications, particularly with regard
to the erosions which occur, would significantly decrease within
12 months postoperatively. The rate of complications was investi-
gated as a secondary endpoint. The results of this investigation
are presented below.Material and Methods
Study design and patients
This national, prospective, multicentre observational study (na-
tional, multicentre post market surveillance study on anterior pel-
vic prolapse reconstruction with a titanium-coated polypropylene
mesh [TiLOOP® PRO A]) was conducted at five German hospitals,
sponsored by pfm medical ag. The inclusion criterion for study
subjects was symptomatic pelvic organ prolapse in the anterior
compartment, that is, a symptomatic cystocele ≥ grade II accord-
ing to the classification of the International Continence Society
(ICS) with the aid of the Pelvic Organ Prolapse Quantification
(POP‑Q-) system [18]. Patients could be included in a primary as
well as in a recurrent situation. Exclusion criteria defined included
family planning which had not yet been completed, a current on-
cological illness in the region of the pelvis/pelvic organs, current
or previous radiation of the pelvis/pelvic organs, previously im-
planted mesh in the anterior compartment, and participation in
another interventional study.
A total of 54 patients were included between February and Au-
gust 2016. The study time period ended in August 2017 with the
12-month follow-up of the last study subjects. All patients were
cognitively able to understand the nature, issue, objective, bene-
fits and risks of the study and study participation and indepen-
dently fill out the necessary questionnaires. The study was ex-
plained to them in detail and in accordance with guidelines, and
the patients were able to withdraw from participation in the study
at any time. All data were collected in accordance with the federal
data protection law. Prior to the start, the study was registered
with the registry of the National Institutes of Health (NIH) (clini-
caltrials.gov: NCT02690220) and reviewed and approved by the
independent ethics committees in the respective federal states
of the study centres. All complications (adverse events, AEs) were
reviewed by an independent committee (clinical event commit-
tee, CEC). 100% monitoring of the study and supervision by the
sponsor took place within the scope of an audit. The improvement
in quality of life 12 months after the surgery, in comparison to be-
fore the surgery, was defined as the primary study objective. Sec-
ondary study objectives were the occurrence of serious and non-
serious complications (serious adverse events [SAEs], non-serious
AEs), the feasibility of the surgery, and the quality of life 6 months
after the implantation. The patients had clinical visits preopera-
tively and 6 and 12 months postoperatively. The prolapse andCadenbach-Blome T et al. Significant Improvement in… Geburtsh Frauenheilk 2019; 79: 959–9the postoperative anatomic result were documented in a stan-
dardised fashion using the POP‑Q system [18,19] and the quality
of life, including changes in sexuality, were queried using the Pro-
lapse Quality of Life (P‑QoL) questionnaire validated in Germany
[20,21]. In addition, the patients underwent clinical visits after
6 weeks.
Implant and surgical technique
Surgical treatment for the cystocele was performed via the vagi-
nal implantation of a titanised polypropylene mesh (TiLOOP®
PRO A, pfm medical ag). In comparison to the implant of the pre-
vious study (TiLOOP® Total 6), the pores of the TiLOOP® PRO‑A im-
plant used here were enlarged (from 1 to 3mm) and the weight
was reduced (from 35 to 24 g/m2). For the 6-point fixation, the in-
troducer sheath was initially placed via transobturator and ischio-
rectal tunnelling following traditional preparation of the cystocele
and then the arms of the mesh were threaded. The mesh was thus
fixed distally in the obturator fascia, laterally on the arcus tendi-
neus in the direct vicinity of the ischial spine and apically in the
sacrospinal ligament in each case on the right as well as the left
(▶ Fig. 1). All patients received perioperative antibiotic treatment;
in addition, if necessary, the surgical treatment of the posterior
compartment, hysterectomy and/or suburethral sling placement
could be performed. Postoperatively, a local vaginal oestrogen
treatment was prescribed.
P‑QoL questionnaire to determine quality of life,
including sexuality
In order to pre- and postoperatively assess the current symptoms
of the prolapse, the severity of the impairment, the effects on the
patientsʼ quality of life and everyday life, the validated German
P‑QoL questionnaire was used [21,23]. In 40 questions, the cur-
rent state of health, negative psychological and physical effects
due to the prolapse, negative effects on role perception and the
partner relationship as well as negative effects on sexuality,
among others, are documented. The scale of results ranges from
0 (no impairment) to 100 (maximum impairment of quality of
life). In order to more accurately record the changes in sexuality,
some specifying questions on sexuality from the validated Ger-
man pelvic floor questionnaire were supplemented [24], e.g.
about dyspareunia or about the location of the pain during sexual
intercourse. Patients were free to not answer individual or all
questions about their quality of life. Sexually inactive patients an-
swered the questions on sexuality with “no information possible”.
Anatomic assessment, clinical examination
The preoperative stage of the prolapse and the postoperative re-
sult were documented according to the standardised, internation-
al prolapse classification of the ICS [18,19]. The POP‑Q system de-
fines 9 points in all 3 compartments, such as vaginal vault or cer-
vix, which are measured in relation to the hymenal ring. In this
way, defects can be assessed quantitatively and reproducibly ac-
cording to site and degree of severity [20]. Prolapse in the anterior
compartment ≥ grade II was defined as a recurrence.96168
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▶ Fig. 1 Fixation points of the mesh (blue markings). Figure from: Wedel T, Pauli F. Anatomische und chirurgische Grundlagen zur Netz-
rekonstruktion des Beckenbodens. Stuttgart: Thieme; 2010 [22], the blue marks of the fixation points were added.
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The adverse events were assessed with the aid of the Common
Terminology Criteria for Adverse Events (CTCAE, Version 0.4)
[25] by an independent, external CEC. The participating experts
had previously confirmed their independence through the disclo-
sure of their (financial) interests and were selected based on their
scientific and medical expertise.
Statistics
The statistical analysis was performed with IBM SPSS®. The Wil-
coxon test was used for the statistical analysis of the change in
quality of life, including sexuality, between the pre- and postoper-
ative time point. The comparison of two random samples was per-
formed with the χ2 test and Fisherʼs exact test. The Wilcoxon test
was used for the analysis of temporal progressions of dependent
groups, for example, for the calculation of changes in the domains
of the P‑QoL questionnaire. The comparison of independent
groups was calculated using the Kruskal-Wallis test, the paired
comparison was calculated with the Mann-Whitney test.962 CadenResults
Demographics
The patientsʼ demographic data were in line with the average
from the census [26] and the data from German hospitals on diag-
nosis-related groups (DRG) provided by the Institute for the Hos-
pital Remuneration System (InEK) [27]. On average, the patients
were 67.5 ± 8.3 years old (50–82), the BMI was 27.7 ± 4.7 kg/m2
(20.2–44.4). They had given birth to an average of 2.3 children
(0–4) and 90.4% (47/52) of the patients had had at least one vagi-
nal delivery; only 1.9% (1/52) had a Caesarean section. One quar-
ter of the patients had previously undergone pessary therapy (13/
52, 25.0%) and/or pelvic floor training (14/52, 26.9%). 30.8% (16/
52) of the patients had undergone hysterectomy and 13.5% (7/
52) had already had surgery due to prolapse. Of 54 patients in-
cluded, 53 underwent surgery between February and August
2016. One patient had already withdrawn consent for study par-
ticipation preoperatively. An alternative mesh implant was usedbach-Blome T et al. Significant Improvement in… Geburtsh Frauenheilk 2019; 79: 959–968
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▶ Fig. 2 Diagram of study participants according to the CONSORT statement, 2010.intraoperatively in one patient. Prior to the 6-month follow-up,
one patient withdrew her consent for participation in the study
due to (S)AEs. One patient had a stroke which led to the end of
study participation. Thus 49 patients completed the 12-month
follow-up, and of these patients, 46 completed the study as usual
via a complete clinical visit and 3 via telephone interview. The pa-
tient cohort is explained in ▶ Fig. 2 in a diagram according to the
CONSORT 2010 statement [28].
Quality of life
In the area of quality of life, the secondary endpoint of the pre-
vious study [11] could be confirmed here as the primary endpoint.
A significant improvement in the quality of life was observed
(p = 0.001, Wilcoxon test). Preoperatively, the negative impact
on life due to the prolapse (83.3/100 points), the negative impact
on roles and physical impairment (66.3 and 60.6/100 points) and
the negative effects on the partner relationship (41.2/100 points)
were the areas of patientsʼ quality of life which were the most af-
fected (▶ Fig. 3). At the 6-month follow-up, a significant improve-
ment could already be determined in these 4 areas (12.9, 7.1 and
9.5 [p < 0.001, Wilcoxon test] and 16.1 out of 100 points in each
case [p = 0.009, Wilcoxon test]). The 12-month follow-up demon-
strated a further significant improvement as compared to the
preoperative survey (▶ Fig. 3). In the other areas investigated as
well (general state of health, social limitation, mood, sleep and
degree of symptoms) this significant improvement could be re-
produced in both follow-ups (baseline vs. 12-month follow-up,
out of 100 points in each case: 38.0 vs. 21.0; 25.2 vs. 6.7; 34.7
vs. 15.2; 38.3 vs. 16.3; 50.8 vs. 13.7).Cadenbach-Blome T et al. Significant Improvement in… Geburtsh Frauenheilk 2019; 79: 959–9Sexuality
In addition to the 3 questions on the P‑QoL on the topic of sexual-
ity (negative effects on the partner relationship and/or sex life,
vaginal bulging which hinders sexual intercourse), eight questions
on sexuality from the validated German pelvic floor questionnaire
were added to the sheet [24]. In addition to questions regarding
vaginal dryness, intravaginal sensation, the sensation of vaginal
width or narrowness, questions regarding pain during intercourse,
location of pain and urine loss during intercourse were asked,
among others. Preoperatively, 26.9% (14/52) of the patients were
sexually active. In the 12-month follow-up, this figure was 44.9%
(22/49). The assessment showed that no preoperatively active pa-
tients indicated sexual inactivity after 12 months. 71.2% (37/52)
of patients indicated being sexually inactive prior to the implanta-
tion, and of them, 15.4% (8/52) indicated this was due to dyspa-
reunia or problems during sexual intercourse. Other reasons for
sexual inactivity included, among others, a lack of partnership,
impotence on the part of the partner, and no interest. 50% (25/
50) of the patients indicated that the prolapse has a negative im-
pact on sex life (10 mild, 7 moderate, 8 severe). In the 12-month
follow-up, 51% (25/49) of the patients indicated being sexually in-
active. Only one patient indicated dyspareunia as the reason for
this. 16.7% (8/48) of the patients indicated that the prolapse has
an influence on sex life (7 mild, 1 moderate), but only 8.7% (4/46)
indicated that they perceived the prolapse as disruptive during in-
tercourse. ▶ Fig. 4 shows the effects of the prolapse on sexual in-
tercourse in the course of the study.96368
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▶ Fig. 5 Anatomical result prior to the implantation as well as 6 and
12 months postoperatively (scale according to ICS classification).Anatomic Result
The degree of prolapse was classified according to the POP‑Q sys-
tem [19]. It significantly improved in all compartments and also
with regard to overall status, after 6 as well as after 12 months.
Preoperatively, 32.7% (17/52) of patients were diagnosed with a
grade II cystocele and 67.3% (35/52) were diagnosed with a grade
III cystocele. 86.5% (45/52) of all patients demonstrated a pro-
lapse of the apical compartment, uterus or vaginal stump (grade
I–III). Prolapse of the posterior compartment (grade I–III) was di-
agnosed in 94.2% (49/52) of the patients. Only 5.8% (3/52) had
no prolapse of the posterior compartment. 3.8% (2/52) of the pa-
tients suffered from grade IV prolapse. Simultaneous procedures
to treat the prolapse in the posterior compartment were per-
formed in 75.0% (39/52) of all surgeries; 57.7% (30/52) of them
were a conventional posterior colporrhaphy, 17.3% (9/52) were a
mesh-aided treatment (TiLOOP® PRO Plus P, pfm medical ag, Co-
logne). 13.5% (7/52) of all patients underwent a hysterectomy.
In the 6-month follow-up, 66.7% (32/48) of the patients did
not demonstrate any cystocele, 33.3% (16/48) had a grade I cys-
tocele. Likewise, 66.7% (32/48) of the patients did not demon-
strate any apical prolapse, while 29.2% (14/48) demonstrated
grade I apical prolapse and 4.2% (2/48) had grade II prolapse. In
the 12-month follow-up, 54.3% (25/46) of the patients did not
demonstrate any cystocele, 41.3% (19/46) had a grade I cystocele
(▶ Fig. 5). 69.6% (32/46) of the patients did not demonstrate any
apical prolapse, 26.1% (12/46) demonstrated grade I apical pro-
lapse. At the 12-month follow-up, 4.3% (2/46) of the patients
were diagnosed with a repeat grade II cystocele combined with
an apical grade II prolapse and a prolapse in the posterior com-
partment. Preoperatively, both patients were status post hyster-
ectomy and a posterior colporrhaphy was performed at the same
time. At the 12-month follow-up, 37% (17/46) of the patients did
not demonstrate any prolapse in the posterior compartment;
43.5% (20/46) had grade I prolapse and 19.6% (9/46) had grade
II prolapse. Of the nine patients with posterior grade II prolapse
at the 12-month follow-up, two already had prolapse of the pos-
terior compartment preoperatively. Two patients did not have any
concomitant procedures, 5 patients underwent posterior colpor-
rhaphy, one patient underwent posterior colporrhaphy and a hys-
terectomy – this patient received a posterior mesh at a later point
in time – and one patient underwent the concomitant implanta-
tion of a posterior mesh.Adverse Events
An independent CEC evaluated each AE and allocated the corre-
sponding organ class according to the CTCAE coding. AEs were
documented at each point in time. By the end of the 12-month
observation period, a total of 23 AEs were reported, of which
2 events were assessed by the CEC as incorrect entries and 2 as
not being AEs. Ultimately, 19 AEs were documented in a total of
15 patients. Eleven events in 10 patients were defined as SAEs
and 8 events in 6 patients were defined as non-serious AEs. None
of the AEs was related to the product. Fourteen AEs were likely or
definitively related to the procedure. All events were able to be al-
located to a total of 8 different organ classes. Most patients wereCadenbach-Blome T et al. Significant Improvement in… Geburtsh Frauenheilk 2019; 79: 959–9affected by AEs of the groups “Impairment of renal and/or blad-
der function” (11.5% [6/52] of the patients) and “Symptoms of
the reproductive system and/or chest discomfort” (5.7% [3/52]).
The number of intra- or perioperative complications was ex-
tremely low. No organ damage was reported. A haematoma
which required revision but not transfusion occurred in one pa-
tient (1.9% [1/52]). 3.8% (2/52) of patients received antibiotic
treatment due to a urinary tract infection. 3.8% (2/52) of the pa-
tients reported more severe postoperative pain (CTCAE grade 3)
in the pelvis. One patient (1.9% [1/52]) suffered continuous urine
voiding disorder. Preoperatively, 53.8% (28/52) of the patients
were continent. 46.2% (24/52) of women suffered from grade I
or II stress incontinence. At the 12-month follow-up, 73.5% (36/
49) of the patients were continent. 58.3% (21/36) of them did
not demonstrate any incontinence symptoms, as was the case
preoperatively. 36.1% (13/36) of the continent women at the 12-
month follow-up did not demonstrate any postoperative symp-
toms of stress incontinence indicated previously, 11.1% (4/36)
had received a suburethral sling placement in the course of the
study. 5.5% (2/36) due to symptoms which already existed preop-
eratively and 5.5% (2/36) due to marked stress incontinence post-
operatively. 26.5% (13/49) of the patients indicated symptoms of
stress incontinence at the time of the 12-month follow-up with-
out the desire for surgical treatment. In 38.4% (5/13) of these
women, masked grade I stress incontinence occurred postopera-
tively; in 61.6% (8/13) of the patients, the stress incontinence
continued unchanged as compared to before the implantation.
At no time in the study did erosion have to be reported as an AE.96568
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The initial cases of surgical treatment of female organ prolapse
using alloplastic materials were published in the mid-1950s. [29].
In these first cases, a tantalum mesh (oxidised metal) was initially
implanted. Then, starting in the early 1960s, the rise of synthetic
sutures and meshes began, initially in surgical hernia surgery but
then also in prolapse surgery [30–33]. Given an ongoing discus-
sion about materials [34] due to the high rate of complications
(dyspareunia, shrinkage, pain, erosions, etc.) the implants were
continuously developed further [35]. In the early 2000s, a
polypropylene mesh with partially absorbable monophilic sutures
and a pore size of 2.5mm was considered to be the optimal mate-
rial for alloplastic tissue replacement in the pelvic floor [36,37],
which is why this type of material was picked up on by many man-
ufacturers and made available on the market in various forms of
application. This and other implants were taken off the market fol-
lowing the warning from the FDA in 2011 [12] because of the
wave of lawsuits in the United States and there was a significant
decrease in mesh-aided prolapse surgeries. The situation in Eu-
rope was different. Although there was also a decrease here in
the total number of implantations, the numbers among users
who regularly performed vaginal mesh surgeries remained con-
stant, as revealed by a survey among members of the Internation-
al Urogynecology Association (IUGA) [38]. These changes can also
be verified for Germany [14]. If an attempt is made in the case of a
method with a high anatomical success rate [39], in comparison
to the conventional surgeries with tightening of the autologous
tissue [3,7], to further reduce the rate of complications through
improved elasticity of the material, enlarged mesh pores and
weight reduction of the implant, new implants have been devel-
oped worldwide through cooperation with experienced mesh sur-
geons and the industry, and the positive effects for patients have
been reappraised in studies [16,40–42].
In the national, multicentre observational study presented
here with 54 included patients, the changes in quality of life, im-
pact on sexuality, the rate of complications and the anatomic re-
sult following implantation of a titanised polypropylene mesh
were investigated in the case of a symptomatic cystocele. The pa-
tient cohort of this study reflects the patient clientele typical for
Germany for the disease [26,27]. The study was designed as a fol-
low-up study to the previous long-term study (clinicaltrials.gov:
NCT01084889) for the investigation of cystocele correction with
an alloplastic mesh (TiLOOP® Total 6, pfm medical ag) also with
obturator, lateral and apical fixation [11,43]. Through the further
improvement of the implant (enlargement of the pores from 1 to
3mm, weight reduction from 35 to 24 g/m2), the positive results
with regard to quality of life this time as the primary endpoint,
sexuality (with an additional questionnaire) [17], and the anatom-
ical result should be confirmed with the simultaneous expectation
that the rate of complications would decrease.
The assessment of the P‑QoL questionnaire on quality of life
demonstrated a significant increase in patientsʼ quality of life
compared to the preoperative questionnaire not only 6 months
postoperatively but also after 12 months. The study was thus able
to confirm other published works and also the data from the pre-
vious study [11,16,43–45]. Overall, it is typical for this patient966 Cadencohort that the majority of the women are not sexually active. In
addition to symptomatic prolapse, the reasons for this are often
problems on the part of the partner, age, or the patientʼs own
state of health. The queries regarding sexuality, which were par-
ticularly detailed due to the addition of another 8 questions, re-
vealed very encouraging results. Postoperatively (44.1%) signifi-
cantly more patients were sexually active than preoperatively
(26.9%). No previously sexually active patient was sexually inac-
tive 12 months postoperatively. Only 2% (1/49) of the patients in-
dicated dyspareunia as the reason for sexual inactivity 12 months
postoperatively; preoperatively, this figure was 15.4%, and no pa-
tient indicated de novo dyspareunia. Given a low number of pa-
tients, this can undoubtedly be seen only as a further indication
of a positive influence on sexuality following vaginal mesh implan-
tation which the TiLOOP®-Total-6 study had already shown with a
positive effect on sexuality [11]. However, it is suspected that the
further change in the implant, especially the greater flexibility due
to the reduced weight, could play a role here. Additional clinical
studies with a larger number of cases are necessary to confirm this
topic and also to compare the various vaginal surgery methods
with one another. The anatomical result was very good. Only
4.3% (2/46) of the patients demonstrated a grade II cystocele
again at the 12-month follow-up. Both patients had undergone
hysterectomy and a posterior colporrhaphy was performed in par-
allel to the mesh implantation. Whether a mesh-aided surgical
treatment of the posterior compartment can decrease the rate
of recurrence even further here should be investigated in addi-
tional studies. Overall, this rate of recurrence, as other studies on
mesh-aided prolapse surgery have shown [11,44,46], is superior
to that of autologous tissue reconstruction in the sense of anterior
colporrhaphy [3,7]. Most of the 19 documented adverse events
which occurred during the 12-month follow-up observation peri-
od can be attributed to the typical complications following surgi-
cal prolapse correction, e.g. urine voiding disorder, masked incon-
tinence, urinary tract infection. There were no adverse events re-
lated to the investigational device. The TiLOOP®-Total-6 study
demonstrated an erosion rate of 10.5% in the first 12 months
[11]. In the widely discussed PROSPECTstudy, the most significant
difference between conventional tightening of autologous tissue
and mesh implantation was the rate of secondary procedures due
to mesh erosion [47]. In the study described here, no individual
cases of erosion occurred within 12 months. Long-term data with
the new mesh implants must still undoubtedly confirm this posi-
tive result on larger numbers of patients. However, the data on
quality of life, sexuality, and the complications presented here
give an indication that, with the further development of implants,
the surgical treatment of pelvic organ prolapse with the implanta-
tion of an alloplastic mesh has had fewer complications and has
become more satisfactory for patients with regard to the post-
operative quality of life, including sexuality. In the past 3 years,
short-term as well as long-term data on vaginal mesh implanta-
tions have been continuously published [43,44–46,48]. This
shows that this surgical method represents a treatment which is
currently widely used. The Association for Urogynaecology
(AGUB) has drawn up a statement on the prohibition by the FDA
since April 2019 of alloplastic meshes for the anterior compart-
ment [49]. Here as well, the guideline-compliant use of alloplasticbach-Blome T et al. Significant Improvement in… Geburtsh Frauenheilk 2019; 79: 959–968
meshes for the surgical correction of pelvic organ prolapse in
women is highlighted as an important treatment option.Conclusion
The surgical treatment of pelvic organ prolapse with the TiLOOP®-
PRO‑A mesh as an alloplastic mesh implant demonstrates a very
good anatomic result with a very low rate of recurrence. In the
hand of the practised surgeon, the method has few complica-
tions. The quality of life improves in all areas significantly and the
effects on sexuality are positive. In accordance with the guide-
lines, each patient should be counselled prior to surgical prolapse
correction using the current data on the risk of recurrence with
and without an implant, rates of complications, and on the thera-
peutic alternatives. It is desirable to offer all current therapeutic
options in a urogynaecological centre. However, current surveys
show that there is little agreement in the treatment of pelvic or-
gan prolapse [50–52]. The data presented here and other long-
term studies which compare methods, among others, should pro-
vide certainty and assistance now and in the future in the selec-
tion of the surgical method, especially for the patients and physi-
cians.
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